Nasdaq

Perspective Therapeutics, Inc. Announces Clinical Updates and Recruitment Progress for Novel Radiopharmaceuticals Ahead of 2025 ASCO Meeting

Perspective Therapeutics, Inc. provided a business update highlighting progress in its clinical trials and manufacturing capabilities as of May 2025. The company is actively enrolling patients in ...
Nasdaq

Perspective Therapeutics Advances [212Pb]VMT-α-NET Phase 1/2a Study to Cohort 3 with Higher Dosing Strategy

Perspective Therapeutics, Inc. announced that its Phase 1/2a clinical trial for [212Pb]VMT-α-NET is moving into Cohort 3, administering a higher fixed dose of 6 mCi for patients with unresectable or ...